These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 30060815)

  • 1. Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.
    Shaw J; Costa-Pinheiro P; Patterson L; Drews K; Spiegel S; Kester M
    Adv Cancer Res; 2018; 140():327-366. PubMed ID: 30060815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel agents targeting bioactive sphingolipids for the treatment of cancer.
    Adan-Gokbulut A; Kartal-Yandim M; Iskender G; Baran Y
    Curr Med Chem; 2013; 20(1):108-22. PubMed ID: 23244584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer and sphingolipid storage disease therapy using novel synthetic analogs of sphingolipids.
    Gatt S; Dagan A
    Chem Phys Lipids; 2012 May; 165(4):462-74. PubMed ID: 22387097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The unfolding role of ceramide in coordinating retinoid-based cancer therapy.
    Ghandour B; Dbaibo G; Darwiche N
    Biochem J; 2021 Oct; 478(19):3621-3642. PubMed ID: 34648006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingolipid metabolism enzymes as targets for anticancer therapy.
    Kok JW; Sietsma H
    Curr Drug Targets; 2004 May; 5(4):375-82. PubMed ID: 15134220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of bioactive sphingolipids in cancer biology and therapeutics.
    Saddoughi SA; Song P; Ogretmen B
    Subcell Biochem; 2008; 49():413-40. PubMed ID: 18751921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysregulation of sphingolipid metabolism in cancer.
    Ryland LK; Fox TE; Liu X; Loughran TP; Kester M
    Cancer Biol Ther; 2011 Jan; 11(2):138-49. PubMed ID: 21209555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sphingolipid targets in cancer therapy.
    Modrak DE; Gold DV; Goldenberg DM
    Mol Cancer Ther; 2006 Feb; 5(2):200-8. PubMed ID: 16505092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sphingolipids and response to chemotherapy.
    Dimanche-Boitrel MT; Rebillard A
    Handb Exp Pharmacol; 2013; (216):73-91. PubMed ID: 23563652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia.
    Ung J; Tan SF; Fox TE; Shaw JJP; Vass LR; Costa-Pinheiro P; Garrett-Bakelman FE; Keng MK; Sharma A; Claxton DF; Levine RL; Tallman MS; Cabot MC; Kester M; Feith DJ; Loughran TP
    Blood Rev; 2022 Sep; 55():100950. PubMed ID: 35487785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer.
    Voelkel-Johnson C; Norris JS; White-Gilbertson S
    Adv Cancer Res; 2018; 140():265-293. PubMed ID: 30060812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sphingosine kinase/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance.
    Selvam SP; Ogretmen B
    Handb Exp Pharmacol; 2013; (216):3-27. PubMed ID: 23563649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceramide synthases: Reflections on the impact of Dr. Lina M. Obeid.
    Kim JL; Mestre B; Shin SH; Futerman AH
    Cell Signal; 2021 Jun; 82():109958. PubMed ID: 33607256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sphingolipid-Transporting Proteins as Cancer Therapeutic Targets.
    Samaha D; Hamdo HH; Wilde M; Prause K; Arenz C
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic implications of bioactive sphingolipids: A focus on colorectal cancer.
    Camp ER; Patterson LD; Kester M; Voelkel-Johnson C
    Cancer Biol Ther; 2017 Sep; 18(9):640-650. PubMed ID: 28686076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug target identification in sphingolipid metabolism by computational systems biology tools: metabolic control analysis and metabolic pathway analysis.
    Ozbayraktar FB; Ulgen KO
    J Biomed Inform; 2010 Aug; 43(4):537-49. PubMed ID: 20348024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceramide Metabolism Enzymes-Therapeutic Targets against Cancer.
    Gomez-Larrauri A; Das Adhikari U; Aramburu-Nuñez M; Custodia A; Ouro A
    Medicina (Kaunas); 2021 Jul; 57(7):. PubMed ID: 34357010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Killing cancer cells by poly-drug elevation of ceramide levels: a hypothesis whose time has come?
    Radin NS
    Eur J Biochem; 2001 Jan; 268(2):193-204. PubMed ID: 11168352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioactive sphingolipids in response to chemotherapy: a scope on leukemias.
    Ekiz HA; Baran Y
    Anticancer Agents Med Chem; 2011 May; 11(4):385-97. PubMed ID: 21453240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interdiction of sphingolipid metabolism to improve standard cancer therapies.
    Beckham TH; Cheng JC; Marrison ST; Norris JS; Liu X
    Adv Cancer Res; 2013; 117():1-36. PubMed ID: 23290775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.